Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


S. Korea Pharmas Benefit From Scare Over H1N1 Flu As Other Firms Hurt

This article was originally published in PharmAsia News

Executive Summary

South Korea's pharmaceutical industry is benefiting from a growing fear of the H1N1 flu at the same time other industries lose business. When the first two South Korean deaths were attributed to the flu, Green Cross, the nation's only drug maker with H1N1 vaccine production facilities, saw a 15 percent jump in the price of its shares, the limit allowed at the stock market. Green Cross currently is negotiating with the government over the price it is be allowed to charge for the vaccine once it is approved, expected by October. Other drug makers, such as Yuhan, are benefiting from ties to multinational drug makers with flu treatments. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts